#1 Clinical Trials Search in Europe

For-6219

FOR-6219 is an innovative drug currently undergoing clinical trials for the treatment of endometriosis. This article provides an overview of the ongoing research, including safety assessments, dosage studies, and potential effects on hormone levels and endometrial tissue. The trials aim to evaluate the drug’s effectiveness and safety profile in both pre- and post-menopausal women, offering hope for those suffering from this challenging condition.

Table of Contents

What is FOR-6219?

FOR-6219 is a new drug being developed to treat endometriosis, a painful condition where tissue similar to the lining of the uterus grows outside the uterus[2]. This drug is currently undergoing clinical trials to evaluate its effectiveness and safety for patients.

How Does FOR-6219 Work?

FOR-6219 is classified as a hydroxysteroid (17B) dehydrogenase (HSD17B1) inhibitor[2]. In simpler terms, this means it targets a specific enzyme in the body that plays a role in producing estrogen. By inhibiting this enzyme, FOR-6219 aims to reduce the production of estrogen, which is believed to fuel the growth of endometriosis tissue.

Clinical Trials

FOR-6219 is currently being studied in several clinical trials to understand its effects, safety, and how it behaves in the body. These trials are divided into different phases:

  • Phase 1/1b Study: This study is designed to investigate the safety, tolerability, and how the drug is processed in the body (pharmacokinetics) of FOR-6219. It also looks at how food affects the drug’s absorption and its effects on the body (pharmacodynamics)[2]. This study includes both post-menopausal and pre-menopausal women.
  • Bioavailability Study: Another study is comparing how well the body absorbs different forms of FOR-6219 (capsules vs. tablets) and how food affects its absorption[1]. This information helps researchers determine the best way to administer the drug.

Dosage and Administration

The clinical trials are testing various dosages of FOR-6219 to determine the most effective and safe dose. The drug is being tested in both capsule and tablet forms, taken orally[1][2]. Some of the dosages being studied include:

  • Single doses ranging from 2 mg to 175 mg
  • Multiple doses of 50 mg once daily, 75 mg twice daily, and 150 mg twice daily

Researchers are also investigating how food affects the absorption of FOR-6219, which will help determine whether the drug should be taken with or without food[1].

Safety and Side Effects

As FOR-6219 is still in clinical trials, its full safety profile is not yet established. The ongoing studies are closely monitoring for any side effects or adverse reactions. Some of the safety measures being evaluated include[2]:

  • Incidence of treatment-emergent adverse events (TEAEs)
  • Changes in laboratory tests (blood and urine tests)
  • Changes in vital signs (blood pressure and heart rate)
  • Changes in electrocardiogram (ECG) readings
  • Any abnormalities detected by transvaginal ultrasound (in pre-menopausal women)

It’s important to note that all new drugs undergo rigorous safety testing before they can be approved for general use.

Future Prospects

The development of FOR-6219 represents a potential new treatment option for women with endometriosis. The drug is being studied for its ability to affect hormone levels and reduce endometrial tissue growth[2]. Researchers are particularly interested in its effects on:

  • Systemic hormone levels (including estradiol, estrone, luteinizing hormone, follicle-stimulating hormone, and progesterone)
  • Endometrial thickness
  • Follicle volume

If successful, FOR-6219 could provide a new way to manage endometriosis symptoms and potentially slow the progression of the condition. However, it’s important to remember that the drug is still in the testing phase, and more research is needed before it can be considered for approval and widespread use.

Aspect Details
Drug Name FOR-6219
Drug Type Hydroxysteroid (17B) dehydrogenase (HSD17B1) inhibitor
Condition Studied Endometriosis
Trial Phases Phase I/Ib
Study Populations Pre-menopausal and post-menopausal women
Formulations Capsule and tablet
Key Outcomes Measured Safety, tolerability, pharmacokinetics, pharmacodynamics, hormone levels, endometrial thickness
Dosing Studies Single ascending doses, multiple ascending doses
Food Effect Studied in some trials

FAQ

  • What is FOR-6219 and what is it being studied for? FOR-6219 is a drug being studied for the treatment of endometriosis. It is a hydroxysteroid (17B) dehydrogenase (HSD17B1) inhibitor, which means it may help regulate hormone levels associated with endometriosis.
  • What types of clinical trials are being conducted for FOR-6219? There are multiple clinical trials for FOR-6219, including Phase I/Ib studies to assess safety, tolerability, food effects, and how the body processes the drug (pharmacokinetics). These trials involve both single and multiple doses in pre- and post-menopausal women.
  • How is the safety of FOR-6219 being evaluated? Safety is being evaluated through various measures, including monitoring for adverse events, checking laboratory safety tests, assessing vital signs, performing ECGs, and conducting transvaginal ultrasounds in some cases.
  • Are there different formulations of FOR-6219 being tested? Yes, FOR-6219 is being tested in both capsule and tablet formulations. One study is specifically comparing the bioavailability of these different formulations and examining how food affects the absorption of the tablet form.
  • What are some of the outcomes being measured in the FOR-6219 trials? The trials are measuring various outcomes, including the drug's concentration in the blood, how quickly it's absorbed and eliminated from the body, its effects on hormone levels, changes in endometrial thickness, and follicle volume in pre-menopausal women.

Ongoing Clinical Trials on For-6219

  • Study on the Effectiveness and Safety of OG-6219 and Naproxen Sodium for Women Aged 18-49 with Moderate to Severe Endometriosis Pain

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Hungary +4

Glossary

  • Endometriosis: A condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility issues.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • HSD17B1 inhibitor: A type of drug that blocks the action of an enzyme involved in hormone production, potentially helping to regulate hormone levels in conditions like endometriosis.
  • Transvaginal ultrasound: An imaging technique used to examine the female reproductive organs by inserting a probe into the vagina.
  • ECG (Electrocardiogram): A test that records the electrical activity of the heart to check for various heart conditions.
  • Cmax: The maximum concentration of a drug observed in the blood after administration.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, used in pharmacokinetic studies.
  • Half-life: The time it takes for the concentration of a drug in the body to be reduced by half.

References

  1. https://clinicaltrials.gov/study/NCT04686669
  2. https://clinicaltrials.gov/study/NCT03709420